{"slug":"gu","tag":"gu","variants":["gu"],"description":"No description yet","count":3,"kinds":{"cancer":3},"related":[],"records":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","tldr":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","tldr":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","tldr":"Kidney cancer is where anti-angiogenic drugs and immunotherapy came together, and where a Nobel-winning oxygen-sensing pathway yielded a drug, belzutifan."}]}